Crohn’s Disease References

Crohn’s Disease References

Crohn disease is a complex, chronic disorder that primarily affects the digestive system. This condition typically involves inflammation of the intestinal track

here are some Crohn’s Disease References the IDEAS has posted

  1.   Baumgart DC; Sandborn WJ (May 2007). “: and established and evolving therapies”. The Lancet 369 (9573): 1641–57.DOI:10.1016/S0140-6736(07)60751-XPMID 17499606.
  2.  Crohn’s Disease Mayo Clinic
  3.  Crohn’s Disease 
  4.  Cho, JH; Brant, SR (2011 May). “Recent insights into the genetics of inflammatory bowel disease.”. Gastroenterology 140 (6): 1704–12. DOI:10.1053/j.gastro.2011.02.046PMID 21530736.
  5.  a b c Dessein, R; Chamaillard M, Danese S (September 2008). “Innate immunity in Crohn’s disease: the reverse side of the medal”. 42 (Suppl 3 Pt 1): S144–7.DOI:10.1097/MCG.0b013e3181662c90PMID 18806708.
  6.  Stefanelli, T; Malesci A; Repici A; Vetrano S; Danese S (2008 May). “ into inflammatory bowel : paving the way for novel ”. Current drug targets 9(5): 413–8. DOI:10.2174/138945008784221170.PMID 18473770.
  7. Marks, DJ; Rahman, FZ, Sewell, GW, Segal, AW (2010 Feb). “Crohn’s disease: an state”. Clinical reviews in allergy & immunology 38 (1): 20–31. DOI:10.1007/s12016-009-8133-2PMID 19437144.
  8.  Mycobacteria in Crohn’s disease: how innate immune deficiency may result in .
  9.  Crohn’s disease: an immune deficiency state.
  10.  Crohn’s disease: Innate immunodeficiency?
  11.  Cosnes J (June 2004). “Tobacco and IBD: relevance in the understanding of and clinical practice”. Best Pract Res Clin Gastroenterol 18 (3): 481–96.DOI:10.1016/j.bpg.2003.12.003PMID 15157822.
  12.  Loftus, EV Jr.; Schoenfeld P; Sandborn WJ (January 2002). “The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review”.Alimentary Pharmacology & Therapeutics 16 (1): 51–60.DOI:10.1046/j.1365-2036.2002.01140.xPMID 11856078.
  13. Bernstein, CN; Wajda, A; Svenson, LW; Mackenzie, A; Koehoorn, M; Jackson, M; Fedorak, R; Israel, D et al. (July 2006). “The epidemiology of inflammatory bowel disease in Canada: a population-based study”. The American Journal of Gastroenterology101 (7): 1559–68. DOI:10.1111/j.1572-0241.2006.00603.x.PMID 16863561.
  14.  a b c d e f g h i Crohn Disease at eMedicine
  15.  Ulcerative colitis at eMedicine
  16.  a b Crohn BB, Ginzburg L, Oppenheimer GD (2000). “Regional ileitis: a pathologic and clinical entity. 1932”. Mt. Sinai J. Med. 67 (3): 263–8. PMID 10828911.
  17.  a b Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer S, Irvine E, Jewell D, Rachmilewitz D, Sachar D, Sandborn W, Sutherland L (2000). “A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998”. Inflamm Bowel Dis 6 (1): 8–15.DOI:10.1002/ibd.3780060103PMID 10701144.
  18. Dubinsky MC, Fleshner PP. (2003). “Treatment of Crohn’s Disease of Inflammatory, Stenotic, and Fistulizing Phenotypes”. Curr Treat Options Gastroenterol 6 (3): 183–200. DOI:10.1007/s11938-003-0001-1PMID 12744819.
  19.  a b c d e f internetmedicin.se > Inflammatorisk tarmsjukdom, kronisk, IBD By Robert Löfberg. Retrieved Oct 2010 Translate.
  20.  a b c d e Hanauer, Stephen B.; William Sandborn (2001-03-01).“Management of Crohn’s disease in adults” (PDF). American Journal of Gastroenterology 96 (3): 635–43. DOI:10.1111/j.1572-0241.2001.03671.xPMID 11280528. Retrieved 2009-11-07.
  21.  a b Pimentel, M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC (2000). “Identification of a prodromal period in Crohn’s disease but not ulcerative colitis”. American Journal of Gastroenterology 95 (12): 3458–62. DOI:10.1111/j.1572-0241.2000.03361.xPMID 11151877.
  22.  Crohn’s Disease Overview
  23.  a b Zieve, David; George F Longstreth (October 18, 2009). “Crohn’s Disease”. ADAM Health Illustrated Encyclopedia. Retrieved 2010-08-16.[verification needed]
  24.  a b c d Podolsky, Daniel K. (2002). “Inflammatory bowel disease”.New England Journal of Medicine 347 (6): 417–29.DOI:10.1056/NEJMra020831PMID 12167685. Retrieved 2006-07-02.
  25. Mueller, MH; Kreis, ME; Gross, ML; Becker, HD; Zittel, TT; Jehle, EC (2002). “Anorectal functional disorders in the absence of anorectal inflammation in patients with Crohn’s disease”. British Journal of Surgery 89 (8): 1027–31. DOI:10.1046/j.1365-2168.2002.02173.x.PMID 12153630.
  26. Kumar, Vinay; Abul K. Abbas, Nelson Fausto (July 30, 2004). “Ch 17: The Gastrointestinal Tract”. Robbins and Cotran: Pathologic Basis of Disease (7th ed.). Philadelphia, Pennsylvania: Elsevier Saunders. pp. 847. ISBN 0-7216-0187-1.
  27. Taylor BA; Williams GT; Hughes LE; Rhodes J (1989). “The histology of anal skin tags in Crohn’s disease: an aid to confirmation of the diagnosis”. Int J Colorectal Dis 4 (3): 197–9.DOI:10.1007/BF01649703PMID 2769004.
  28. Fix, OK; Soto JA; Andrews CW; Farraye FA (2004). “Gastroduodenal Crohn’s disease”. Gastrointestinel Endoscopy 60 (6): 985.DOI:10.1016/S0016-5107(04)02200-XPMID 15605018.
  29.  a b Beattie, RM; Croft NM; Fell JM; Afzal NA; Heuschkel RB (2006).“Inflammatory bowel disease”. Archives of Disease in Childhood91 (5): 426–32. DOI:10.1136/adc.2005.080481PMC 2082730.PMID 16632672.
  30. ^ Büller, H.A. (1997). “Problems in diagnosis of IBD in children”. The Netherlands Journal of Medicine 50 (2): S8–S11.DOI:10.1016/S0300-2977(96)00064-2PMID 9050326.
  31. ^ O’Keefe, S. J. (1996). “Nutrition and gastrointestinal disease”.Scandinavian Journal of Gastroenterology Supplement 31 (220): 52–9. DOI:10.3109/00365529609094750PMID 8898436.
  32. ^ Danese, S; Semeraro S; Papa A; Roberto I; Scaldaferri F; Fedeli G; Gasbarrini G; Gasbarrini A (2005). “Extraintestinal manifestations in inflammatory bowel disease”. World Journal of Gastroenterology11 (46): 7227–36. PMID 16437620. Retrieved 2009-11-07.
  33.  a b Crohn’s disease. professionals.epilepsy.com. Retrieved July 13, 2007.
  34.  MedlinePlus Encyclopedia Small bowel bacterial overgrowth
  35. Zadik Y, Drucker S, Pallmon S (Aug 2011). “Migratory stomatitis (ectopic geographic tongue) on the floor of the mouth”. J Am Acad Dermatol 65 (2): 459–60. DOI:10.1016/j.jaad.2010.04.016.PMID 21763590.
  36. Prevalence defined as at least 5 health care contacts in a 10 year period for the condition, according to: Greenstein, A. J.; Janowitz, H. D.; Sachar, D. B. (1976). “The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients”.Medicine 55 (5): 401–412. DOI:10.1097/00005792-197609000-00004PMID 957999edit
  37.  Enterovesical Fistula at eMedicine
  38.  Ekbom A, Helmick C, Zack M, Adami H (1990). “Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement”.Lancet 336 (8711): 357–9. DOI:10.1016/0140-6736(90)91889-I.PMID 1975343.
  39.  Collins P, Mpofu C, Watson A, Rhodes J (2006). Watson, Alastair J. ed. “Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease”. Cochrane Database Syst Rev (2): CD000279. DOI:10.1002/14651858.CD000279.pub3.PMID 16625534.
  40. Lynne V McFarland (2008). “Colorectal cancer and dysplasia in inflammatory bowel disease”. World Journal of Gastroenterology: 2665.
  41.  Evans J, Steinhart A, Cohen Z, McLeod R (2003). “Home total parenteral nutrition: an alternative to early surgery for complicated inflammatory bowel disease”. J Gastrointest Surg 7 (4): 562–6.DOI:10.1016/S1091-255X(02)00132-4PMID 12763417.
  42.  “Complications of Crohn’s Disease”Centocor Ortho Biotech. Retrieved 2009-11-07.
  43. Kaplan, C (2005-10-21). “IBD and Pregnancy: What You Need to Know”Crohn’s and Colitis Foundation of America. Retrieved 2009-11-07.
  44.  a b c d Kornbluth, Asher; David B. Sachar (July 2004). “Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee”. American Journal of Gastroenterology 99 (7): 1371–85. DOI:10.1111/j.1572-0241.2004.40036.xPMID 15233681Archived from the original on April 6, 2008. Retrieved 2009-11-07.
  45.  Crohn’s Disease Overview
  46. Braat H, Peppelenbosch MP, Hommes DW (August 2006). “Immunology of Crohn’s disease”. Ann. N. Y. Acad. Sci. 1072: 135–54. DOI:10.1196/annals.1326.039PMID 17057196.
  47. Henckaerts L, Figueroa C, Vermeire S, Sans M (May 2008). “The role of genetics in inflammatory bowel disease”. Curr Drug Targets 9(5): 361–8. DOI:10.2174/138945008784221161.PMID 18473763.
  48.  a b c Marks DJ, Harbord MW, MacAllister R, Rahman FZ, Young J, Al-Lazikani B, Lees W, Novelli M, Bloom S, Segal AW (2006).“Defective acute inflammation in Crohn’s disease: a clinical investigation”. Lancet 367 (9511): 668–78. DOI:10.1016/S0140-6736(06)68265-2PMC 2092405PMID 16503465.
  49.  Comalada M, Peppelenbosch MP (September 2006). “Impaired innate immunity in Crohn’s disease”. Trends Mol Med 12 (9): 397–9.DOI:10.1016/j.molmed.2006.07.005PMID 16890491.
  50.  “Crohn’s disease has strong genetic link: study”Crohn’s and Colitis Foundation of America. 2007-04-16. Retrieved 2009-11-07.
  51. Ogura, Y; Bonen, DK; Inohara, N; Nicolae, DL; Chen, FF; Ramos, R; Britton, H; Moran, T et al. (2001). “A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease”. Nature 411(6837): 603–6. DOI:10.1038/35079114PMID 11385577.
  52.  Cuthbert A, Fisher S, Mirza M et al. (2002). “The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease”. Gastroenterology 122 (4): 867–74.DOI:10.1053/gast.2002.32415PMID 11910337.
  53.  Kaser, A; Lee, AH; Franke, A; Glickman, JN; Zeissig, S; Tilg, H; Nieuwenhuis, EES; Higgins, DE et al. (5 September 2008). “XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease”. Cell 134 (5): 743–56.DOI:10.1016/j.cell.2008.07.021PMC 2586148.PMID 18775308.
  54. Clevers, H (2009). “Inflammatory Bowel Disease, Stress, and the Endoplasmic Reticulum”. New England Journal of Medicine 360 (7): 726–27. DOI:10.1056/NEJMcibr0809591PMID 19213688.
  55.  Marks DJ, Segal AW. (January 2008). “Innate immunity in inflammatory bowel disease: a disease hypothesis”. J Pathol. 214(2): 260–6. DOI:10.1002/path.2291PMC 2635948.PMID 18161747.
  56.  Cobrin GM, Abreu MT (2005). “Defects in mucosal immunity leading to Crohn’s disease”. Immunol. Rev. 206: 277–95.DOI:10.1111/j.0105-2896.2005.00293.xPMID 16048555.
  57.  a b Elson, CO; Cong, Y; Weaver, CT; Schoeb, TR; Mcclanahan, TK; Fick, RB; Kastelein, RA (2007). “Monoclonal Anti–Interleukin 23 Reverses Active Colitis in a T Cell–Mediated Model in Mice”.Gastroenterology 132 (7): 2359–70.DOI:10.1053/j.gastro.2007.03.104PMID 17570211.
  58.  Prescott NJ, Fisher SA, Franke A et al. (2007). “A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn’s disease and is independent of CARD15 and IBD5”. Gastroenterology 132 (5): 1665–71. DOI:10.1053/j.gastro.2007.03.034PMID 17484864.
  59.  Moises Velasquez-Manoff (June 29, 2008). “The Worm Turns”.The New York Times.
  60.  Sartor, R. (July 2006). “Mechanisms of Disease: pathogenesis of Crohn’s disease and ulcerative colitis”. Nature Clinical Practice Gastroenterology & Hepatology 3 (7): 390–407.DOI:10.1038/ncpgasthep0528PMID 16819502.
  61.  Naser SA, Collins MT (2005). “Debate on the lack of evidence of Mycobacterium avium subsp. paratuberculosis in Crohn’s disease”.Inflamm. Bowel Dis. 11 (12): 1123.DOI:10.1097/01.MIB.0000191609.20713.eaPMID 16306778.
  62.  http://www.paratuberculosis.info/web/images/proc11/108.pdf
  63. http://www.ncbi.nlm.nih.gov/pubmed/17317344
  64. http://www.ncbi.nlm.nih.gov/pubmed/21990211?dopt=Abstract
  65. Giaffer MH, Clark A, Holdsworth CD (1992). “Antibodies to Saccharomyces cerevisiae in patients with Crohn’s disease and their possible pathogenic importance”. Gut 33 (8): 1071–5.DOI:10.1136/gut.33.8.1071PMC 1379444PMID 1398231.
  66. Baumgart M et al. (2007). “Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn’s disease involving the ileum”. The ISME Journal 1 (5): 403–18.DOI:10.1038/ismej.2007.52PMID 18043660.
  67.  “Possible links between Crohn’s disease and Paratuberculosis”. European Commission Directorate-General Health & Consumer Protection. Retrieved 2009-11-07.
  68.  Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J (March 1997). “Two-year-outcomes analysis of Crohn’s disease treated with rifabutin and macrolide antibiotics” (PDF). J. Antimicrob. Chemother. 39 (3): 393–400.DOI:10.1093/jac/39.3.393PMID 9096189.
  69. Cenac N, Andrews CN, Holzhausen M et al. (March 2007). “Role for protease activity in visceral pain in irritable bowel syndrome”. J. Clin. Invest. 117 (3): 636–47. DOI:10.1172/JCI29255.PMC 1794118PMID 17304351.
  70.  Cenac N, Coelho AM, Nguyen C et al. (November 2002). “Induction of Intestinal Inflammation in Mouse by Activation of Proteinase-Activated Receptor-2”. Am. J. Pathol. 161 (5): 1903–15.DOI:10.1016/S0002-9440(10)64466-5PMC 1850779.PMID 12414536.
  71.  Boorom KF, Smith H, Nimri L et al. (October 2008). “Oh my aching gut: irritable bowel syndrome, Blastocystis, and asymptomatic infection”. Parasit Vectors 1 (1): 40. DOI:10.1186/1756-3305-1-40PMC 2627840PMID 18937874.
  72.  Hugot, JP; Alberti, C; Berrebi, D; Bingen, E; Cézard, JP (2003-12-13). “Crohn’s disease: the cold chain hypothesis”. The Lancet 362(9400): 2012–2015. DOI:10.1016/S0140-6736(03)15024-6.
  73.  “Fridges blamed for Crohn’s disease rise”. Medical News Today. 2003-12-12.
  74.  Forbes, A; Kalantzis, T (July 2006). “Crohn’s disease : the cold chain hypothesis”. International Journal of Colorectal Disease(Springer Berlin / Heidelberg) 21 (5): 399–401. DOI:10.1007/s00384-005-0003-7ISSN 0179-1958PMID 16059694.
  75. ^ Subramanian, S; Roberts, CL; Hart, CA; Martin, HM; Edwards, SW; Rhodes, JM; Campbell, BJ (February 2008). “Replication of Colonic Crohn’s Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics”.Antimicrobial Agents and Chemotherapy 52 (2): 427–34.DOI:10.1128/AAC.00375-07PMC 2224732PMID 18070962.
  76.  Mpofu, CM; Campbell, BJ; Subramanian, S; Marshall–Clarke, S; Hart, CA; Cross, A; Roberts, CL; McGoldrick, A et al. (2007).“Microbial Mannan Inhibits Bacterial Killing by Macrophages: A Possible Pathogenic Mechanism for Crohn’s Disease”.Gastroenterology 133 (5): 1487–98.DOI:10.1053/j.gastro.2007.08.004PMID 17919633.
  77.  “New insights into Crohn’s Disease”.

Leave a Reply